Site Navigation
General Information
Category: biotechnology & health
BSA 10-13: Direct determination of methylation of CpG dinucleotides
BNL Reference Number: BSA 10-13
Patent Status: Application Number 20120219942 was published on August 30, 2012
Summary
McrA binds to the methylated sequence 5'-CmeCpGG-3' under specific situations which make it possible to directly assess the methylation state of any particular CpG island of interest.
Description
The comparative activity of the McrA protein for the 5'-CmeCpGG-3' sequence has been discovered. The protein will specifically bind to double stranded fully and hemi-methylated sequences. To bind hemi-methylated double stranded DNA, the methyl-C of one strand must be opposite a G or an I. If it is complement mis-matched, McrA will not bind.
Benefits
Using specific probes designed for complementarity or for mis-match enable direct determination of the methylation status of each CCpGG sequence in the island.
Applications and Industries
Diagnosis and prognosis and treatment design more and more frequently are being directed by methylation status. This technology enhances the armamentarium for cancer diagnostics.
Have Questions?
For more information about this technology, contact Christine Brakel, (631) 344-7134.
Tags: CpG methylation, diagnostic
